In this week’s Peer Review: Viking’s commercial chief exits after nine months and Gilead taps a BeOne exec for China expansion.

Bob Foster, the acting general counsel at HHS, has left the department.

New data on RevMed’s Rasonque suggest there may be room for other KRAS drugs in pancreatic cancer.

Lilly-backed TRexBio raised $117M in its IPO for Treg drugs in autoimmune disease.

Exclusive: GSK is the latest pharma to partner with AI startup Chai Discovery, which has now signed six such deals in nine months.

Endeavor says its IPF drug met the main goal of a Phase 2b trial and could reverse the disease, not just slow it.

The WHO released a global roadmap for preeclampsia, a pregnancy disorder long ignored by drugmakers but now drawing biopharma interest.

Roche has now done four China deals in seven weeks. Its latest is with little-known Defand on molecular glue degraders.

Argenx halted a Phase 3 Vyvgart trial in Sjögren's after a futility analysis, overshadowing a Phase 2 win in celiac disease.

TCGX is doubling down on China with a $600M Asia fund. Founder Chen Yu calls it his fastest raise in a quarter-century of investing.

MimiVax's glioblastoma vaccine narrowly missed its Phase 2b goal but showed a four-month survival benefit in patients 65 and under.

Caribou is shelving two allogeneic CAR-T programs and weighing a sale or merger after failing to secure funding.

A drug pricing group pressing Congress won't say who funds it, and its DC address is a mailbox at a UPS store.

AstraZeneca opened a $1B R&D site in Cambridge, Mass. “We are here mostly because science is here, because talent is here,” said CEO Pascal Soriot.

ArriVent, an early adopter of the China licensing model, saw its lead lung cancer drug fail a Phase 3 trial. Shares fell 58%.

AbbVie and Genmab's Epkinly cut the risk of progression or death by 51% in first-line DLBCL, setting up a challenge to Roche's Polivy.

Lycia, built on Nobel laureate Carolyn Bertozzi's protein degradation science, filed for an IPO as TRexBio and Retension set terms.

Shionogi is buying IntraBio for $2B upfront, adding the approved rare disease drug Aqneursa to its growing portfolio.